Skip to main content
Clinical Trials/CTRI/2020/12/029739
CTRI/2020/12/029739
Completed
Phase 3

A multicentric, randomized, double-blind, parallel, comparative study to demonstrate the non-inferiority of fixed-dose combination of Efonidipine 40 mg and Telmisartan 40 mg tablets to fixed-dose combination of Cilnidipine 10 mg and Telmisartan 40 mg tablets in the management of patients with Stage II hypertension.

Zuventus Healthcare Limited0 sites240 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Zuventus Healthcare Limited
Enrollment
240
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
July 15, 2021
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Adults (aged \>\=18 years) treatment naïve patients.
  • 2\. Patients diagnosed with Stage\-II hypertension (SBP/DBP: \>\=160/100 mmHg)
  • 3\. Patients willing to sign informed consent

Exclusion Criteria

  • 1\. Patients with known hypersensitivity to angiotensin II receptor blockers or dihydropyridine calcium channel blockers.
  • 2\. Patients with history of severe, malignant or secondary hypertension.
  • 3\. Patient with cerebrovascular disease in the previous 3 months.
  • 4\. Patients with chronic arrhythmia, sick sinus syndrome or sinus bradycardia ( \< 50 beats/min).
  • 5\. Patients with second\- or third\-degree atrioventricular block.
  • 6\. Female patients who are pregnant, lactating.

Outcomes

Primary Outcomes

Not specified

Similar Trials